Tag: Vaccines

Mistrust in health care and government, concerns over vaccine safety and long-term effects among top factors

Postmarketing observation shows increased risk for Guillain-Barré syndrome for 42 days postvaccination

Of children with minimum age or minimum interval invalid dose, almost 50 percent receive extra doses

Findings seen within a single health care system during the early period of availability

Median four-week preF IgG fold rise was 4.21; 61 percent of participants achieved seroconversion

Increases seen in acceptance for new respiratory syncytial virus vaccines

Vaccine effectiveness of 52.8 percent seen for ED visits, 52.3 percent for noncritical hospitalization, 50.4 percent for critical hospitalization

Vaccine effectiveness 91 percent using strict controls in a population of adults aged 60 years or older

ACIP recommends extending interval for two-dose series and adding three-dose series in accordance with FDA label